KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Revenue (2017 - 2025)

Biomarin Pharmaceutical's Revenue history spans 16 years, with the latest figure at $874.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 17.03% year-over-year to $874.6 million, compared with a TTM value of $3.2 billion through Dec 2025, up 12.87%, and an annual FY2025 reading of $3.2 billion, up 12.87% over the prior year.
  • Revenue for Q4 2025 was $874.6 million at Biomarin Pharmaceutical, up from $776.1 million in the prior quarter.
  • The five-year high for Revenue was $874.6 million in Q4 2025, with the low at $408.7 million in Q3 2021.
  • Average Revenue over 5 years is $621.8 million, with a median of $595.8 million recorded in 2023.
  • Year-over-year, Revenue fell 14.27% in 2021 and then increased 28.28% in 2024.
  • Tracing BMRN's Revenue over 5 years: stood at $449.8 million in 2021, then rose by 19.5% to $537.5 million in 2022, then increased by 20.22% to $646.2 million in 2023, then rose by 15.65% to $747.3 million in 2024, then grew by 17.03% to $874.6 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Revenue are $874.6 million (Q4 2025), $776.1 million (Q3 2025), and $825.4 million (Q2 2025).